The black market discovered retatrutide before Eli Lilly did. The Indianapolis-based pharmaceutical company filed six lawsuits on Wednesday against American businesses it claims are selling illicit versions of its still-experimental obesity medication, a substance that has not received approval from any global regulatory body. Given the developments in the GLP-1 space over the past few years, the move seems less surprising and more inevitable.
Retatrutide, sometimes referred to as a “triple-G” medication because it targets three distinct hormone receptors simultaneously, has demonstrated truly remarkable outcomes in clinical trials, with some patients experiencing weight loss that is comparable to that of bariatric surgery.
Data of that type moves quickly. Regulations be damned, someone will attempt to fill a supply gap when there is exceptional demand. Over 690 shipments of illegal GLP-1 products totaling over 31,000 units were intercepted by U.S. Customs and Border Protection in fiscal year 2025, tho it’s still unclear how many people have actually taken black-market versions of this compound. Those figures more than doubled in July alone.
The six businesses listed in Lilly’s lawsuits—Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co.—represent a sizable portion of the gray market involved.
Pharmacies that compound. Spas for medical purposes. Online peptide vendors use phrases like “for research use only,” which has long served as a legitimate cover for dubious quality. Some of these were not dark basement operations, according to a CBS News investigation conducted earlier this year. Numerous clinics had a polished appearance, had appropriate websites, and presented themselves as reputable healthcare providers.
The fact that retatrutide is still undergoing Phase 3 trials makes this especially unsettling to consider. The information is still being assembled. It is anticipated that Lilly will submit a regulatory application next year. This implies that no one with significant authority to do so has checked the purity, dosage accuracy, or safety of anything being bought through these channels. “Every time someone takes one of these, they’re exposing themselves to a huge amount of risk,” stated Dr. Max Denning, Associate Vise President for Global Patient Safety in Cardiometabolic Health at Lilly’s. It’s difficult to disagree.
Even tho Lilly’s legal case seems simple, there is a larger context that makes its position more difficult. During the early GLP-1 shortage years, when Lilly and Novo Nordisk were unable to produce enough tirzepatide and semaglutide to meet demand, the compounding pharmacy industry really took off. Few options were available to patients who were unable to obtain approved medications. Compounders were used by some. Even after the FDA declared the shortage to be over, some people are still using them. The habit developed, and habits are difficult to break.
More than 200 people and organizations have been referred to the FDA, the Justice Department, state attorneys general, and law enforcement, according to Lilly. Additionally, it has identified over 14,000 websites, advertisements, social media posts, and product listings in over 100 countries. In addition to the lawsuits, the company is urging shipping companies, credit card companies, social media companies, and payment processors to step up their enforcement. That’s a large coalition to assemble, and even with everything in motion, the enforcement gaps might still exist.
Watching this play out gives the impression that Lilly is fighting on several fronts at once, including in court, with regulators, and on digital platforms, and that the battle itself says something about the current state of American healthcare. There is a genuine and pressing need for efficient obesity treatments. The formal system is slow. Additionally, some people will take risks that the data does not yet support because of that gap. That tension won’t be resolved by the Lilly retatrutide lawsuits. However, they do demonstrate that someone is at last drawing a clearer line.
